[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-adenoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-adenoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100605358","argon-plasma-coagulation-versus-endoscopic-mucosal-resection-for-gastric-adenoma-cler-ga-100605358",false,"NCT07161479","Argon Plasma Coagulation Versus Endoscopic Mucosal Resection for Gastric Adenoma (CLER-GA)","A Multicenter, Randomized, Single-Blinded Trial Comparing Argon Plasma Coagulation and Endoscopic Mucosal Resection for Gastric Adenoma With Low-Grade Dysplasia","Inclusion Criteria:\n\n* Adults aged 20 years or older\n* Diagnosed with gastric adenoma with low-grade dysplasia measuring ≤ 1 cm on endoscopy\n* Scheduled to undergo endoscopic treatment\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Previous treatment for gastric adenoma or gastric cancer\n* History of gastrectomy\n* Diagnosis of gastric cancer or high-grade dysplasia at the time of enrollment\n* Presence of multiple gastric adenomas\n* Pregnant, breastfeeding, or possibility of pregnancy\n* Uncontrolled chronic illnesses that may interfere with trial participation (e.g., uncontrolled hypertension, uncontrolled diabetes, chronic kidney disease, ascites, heart failure, psychiatric disorders)","ALL","20 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"NA","Gastric adenomas with low-grade dysplasia (LGD) are considered precancerous lesions of the stomach. While these lesions carry a lower risk of progressing to gastric cancer compared with high-grade dysplasia, there is still uncertainty about the best way to manage them. International medical guidelines differ in their recommendations, and for very small lesions (1 cm or smaller), some guidelines provide no clear direction. This creates uncertainty for both patients and physicians about whether to treat these lesions or simply observe them over time.\n\nTwo endoscopic treatment methods are widely used in clinical practice: endoscopic mucosal resection (EMR) and argon plasma coagulation (APC). EMR involves lifting and cutting out the lesion. Its major advantage is that it removes the lesion completely and allows for detailed pathological examination. However, EMR can be technically more demanding, takes more time, and may carry higher risks of complications such as bleeding or perforation. It also usually involves higher medical costs.\n\nIn contrast, APC is a technique that uses ionized argon gas and electrical current to coagulate tissue without direct contact. APC is simpler to perform, takes less time, and is generally less invasive. Patients undergoing APC may have shorter hospital stays, lower costs, and fewer complications. However, APC does not provide a specimen for pathology, so complete removal of the lesion cannot be confirmed. This means there is a possibility of local recurrence.\n\nSeveral retrospective studies have examined APC for gastric LGD, and results have suggested it may be effective for small lesions. However, recurrence rates reported in previous studies have varied widely, from less than 2% to more than 20%. Importantly, no large randomized controlled trial has directly compared APC with EMR for small gastric LGD lesions. This study seeks to fill that gap.\n\nThe goal of this clinical trial is to compare the effectiveness and safety of APC and EMR for treating gastric adenomas that are 1 cm or smaller with low-grade dysplasia. Specifically, the study aims to determine whether APC is \"non-inferior\" to EMR in preventing local recurrence of these lesions. In other words, researchers want to know if APC works just as well as EMR in controlling the disease, while also offering potential advantages such as fewer complications, shorter procedure time, and lower costs.\n\nParticipants in this study will:\n\nBe adults (age 20 or older) diagnosed with a gastric adenoma 1 cm or smaller with low-grade dysplasia.\n\nBe randomly assigned (by chance, like flipping a coin) to receive either APC or EMR.\n\nReceive standard medical care after the procedure, including medications to help the stomach heal.\n\nReturn for follow-up endoscopy at 3 months and 12 months after the procedure. During these visits, the treated area will be checked carefully, and biopsies may be taken to determine whether the lesion has recurred.\n\nProvide information about any complications, the duration of the procedure, and their recovery experience.\n\nThe main question is whether APC can prevent recurrence of gastric adenomas as effectively as EMR. Secondary questions include how the two treatments differ in terms of complications (such as bleeding or perforation) and procedure time.\n\nBoth APC and EMR are already established and commonly used treatments for gastric lesions. By directly comparing these two methods in a randomized controlled trial, this study will provide important evidence to guide future recommendations for patients with small gastric adenomas. The findings may help physicians and patients choose the best treatment option, balancing safety, effectiveness, and convenience.",[26,27,28,29],"Gastric Adenoma","Stomach Neoplasms","Precancerous Conditions","Dysplasia Stomach",[31,32,33,34,35,36,37,38,39],"Gastric adenoma","Low-grade dysplasia","Precancerous gastric lesion","Argon plasma coagulation (APC)","Endoscopic mucosal resection (EMR)","Endoscopic therapy","Local recurrence","Randomized controlled trial","Stomach neoplasms","RECRUITING","2026-02-04",{"date":43,"type":44},"2026-02-06","ACTUAL",{"date":46,"type":44},"2026-01-20",{"date":48,"type":20},"2026-10",{"name":50,"class":51},"Samsung Medical Center","OTHER",3,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100413599","clinical-application-of-genetic-sequencing-of-early-gastric-cancer-and-gastric-adenoma-patients-100413599","NCT04665687","Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients","Clinical Sequencing Project for Early Gastric Cancer and Precancerous Gastric Adenoma Patients for Personalized Cancer Clinic","Inclusion Criteria:\n\n1. Those who are over the age of 19\n2. Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma\n3. Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy\u002Fendodoscopic removal for treatment and diagnosis\n4. Those whose life expectancy is more than 3 months\n5. Those who have voluntarily consented to participate in this clinical trial\n\nExclusion Criteria:\n\n1. Those who will not yield enough samples\n2. Those who are considered inappropriate for this study in the discretion of the researchers","19 Years","100 Years",{"count":63,"type":20},1730,"OBSERVATIONAL","Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence.\n\nLiquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.",[67,26],"Early Gastric Cancer","2025-09-06",{"date":70,"type":44},"2025-09-12",{"date":72,"type":44},"2020-12-17",{"date":74,"type":20},"2031-12-31",{"name":50,"class":51},1]